<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SF3B1 mutations were recently reported in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs), especially in the presence of ring sideroblasts (RSs) </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to define the interaction between SF3B1 mutations, <z:mp ids='MP_0000002'>morphology</z:mp>, karyotype, and prognosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with more than or equal to 15% RS (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RS) </plain></SENT>
<SENT sid="2" pm="."><plain>We studied 107 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RS, including 48 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with RS (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 43 with refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>)-RS, 11 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-1 (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e>)-RS, and 5 with <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e>-RS </plain></SENT>
<SENT sid="3" pm="."><plain>SF3B1 mutations were detected in 53 (âˆ¼ 50%) patients: 35 RARS (73%), 16 RCMD-RS (37%), and 2 RAEB1-RS (18%) </plain></SENT>
<SENT sid="4" pm="."><plain>In univariate analysis, the presence of SF3B1 mutations was associated with better overall (P &lt; .01) and <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free (P &lt; .01) survival; however, in both instances, significance was completely accounted for by World Health Organization morphologic risk categorization </plain></SENT>
<SENT sid="5" pm="."><plain>In other words, when <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> and <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations </plain></SENT>
</text></document>